Insider Buying: Nymox Pharmaceutical Corp (NYMX) Director Acquires 7,000 Shares of Stock

Nymox Pharmaceutical Corp (NASDAQ:NYMX) Director James George Robinson acquired 7,000 shares of the business’s stock in a transaction dated Tuesday, November 13th. The stock was purchased at an average price of $2.00 per share, with a total value of $14,000.00. Following the completion of the transaction, the director now directly owns 3,229,913 shares of the company’s stock, valued at approximately $6,459,826. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

James George Robinson also recently made the following trade(s):

  • On Friday, November 9th, James George Robinson acquired 13,000 shares of Nymox Pharmaceutical stock. The stock was purchased at an average price of $2.09 per share, with a total value of $27,170.00.
  • On Wednesday, November 7th, James George Robinson acquired 363 shares of Nymox Pharmaceutical stock. The stock was purchased at an average price of $2.04 per share, with a total value of $740.52.
  • On Friday, November 2nd, James George Robinson acquired 7,000 shares of Nymox Pharmaceutical stock. The stock was purchased at an average price of $1.98 per share, with a total value of $13,860.00.
  • On Wednesday, October 31st, James George Robinson acquired 12,000 shares of Nymox Pharmaceutical stock. The stock was purchased at an average price of $1.79 per share, with a total value of $21,480.00.
  • On Thursday, October 25th, James George Robinson acquired 10,000 shares of Nymox Pharmaceutical stock. The stock was purchased at an average price of $1.62 per share, with a total value of $16,200.00.
  • On Monday, October 22nd, James George Robinson acquired 8,000 shares of Nymox Pharmaceutical stock. The stock was purchased at an average price of $1.67 per share, with a total value of $13,360.00.

Nymox Pharmaceutical stock traded down $0.03 during mid-day trading on Thursday, hitting $1.96. 813 shares of the company traded hands, compared to its average volume of 140,390. Nymox Pharmaceutical Corp has a one year low of $1.49 and a one year high of $4.60.

Nymox Pharmaceutical (NASDAQ:NYMX) last announced its earnings results on Monday, August 13th. The biopharmaceutical company reported ($0.04) earnings per share (EPS) for the quarter. Nymox Pharmaceutical had a negative net margin of 3,455.58% and a negative return on equity of 4,095.76%. The company had revenue of $0.09 million for the quarter.

A number of institutional investors have recently made changes to their positions in NYMX. BlackRock Inc. lifted its position in Nymox Pharmaceutical by 22.7% during the second quarter. BlackRock Inc. now owns 1,618,459 shares of the biopharmaceutical company’s stock valued at $5,437,000 after purchasing an additional 299,752 shares during the last quarter. Bank of America Corp DE lifted its position in Nymox Pharmaceutical by 648.6% during the second quarter. Bank of America Corp DE now owns 58,623 shares of the biopharmaceutical company’s stock valued at $197,000 after purchasing an additional 50,792 shares during the last quarter. Brown Advisory Inc. bought a new stake in Nymox Pharmaceutical during the first quarter valued at approximately $113,000. Finally, Northern Trust Corp lifted its position in Nymox Pharmaceutical by 8.7% during the second quarter. Northern Trust Corp now owns 272,825 shares of the biopharmaceutical company’s stock valued at $916,000 after purchasing an additional 21,828 shares during the last quarter. Institutional investors and hedge funds own 7.17% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This article was published by WKRB News and is owned by of WKRB News. If you are reading this article on another website, it was stolen and reposted in violation of international trademark and copyright laws. The correct version of this article can be accessed at https://www.wkrb13.com/2018/11/15/insider-buying-nymox-pharmaceutical-corp-nymx-director-acquires-7000-shares-of-stock.html.

Nymox Pharmaceutical Company Profile

Nymox Pharmaceutical Corporation, a biopharmaceutical company, engages in the research and development of drugs for the aging population. It markets NicAlert and TobacAlert test strips that use urine or saliva to detect use of tobacco products. The company also offers AlzheimAlert, a proprietary urine assay that aids physicians in the diagnosis of Alzheimer's disease.

Read More: What is the NASDAQ Stock Market?

Insider Buying and Selling by Quarter for Nymox Pharmaceutical (NASDAQ:NYMX)

Receive News & Ratings for Nymox Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nymox Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply